In fact, the platform of epigenetic regulatory factors and their mRNA levels profiling in a big cohort of MTC tissues has revealed the fact that overexpression of two histone methyltransferases, EZH2 and SMYD3, is connected with higher risk of metastases, disease consistency, and finally death of patients: These can be prognostic biomarkers for MTC[76,88]. This evidence concerns the gene SMYD3 and medullary thyroid gland carcinoma.